Prom1 mutations cause retinal dystrophies like Stargardt disease and cone-rod dystrophy .
mAB 13A4 underestimates PROM1 levels in photoreceptors by ~5-fold compared to ab27699 due to alternative splicing in the third extracellular domain .
Structural epitope dependency limits mAB 13A4’s utility in detecting certain isoforms, necessitating complementary antibodies .
PROM1 is a biomarker for cancer stem cells in gliomas, melanomas, and hepatic tumors .
TA399730 and CD133 HB#7 are used to isolate PROM1+ cells, which drive tumorigenesis and chemoresistance .
Paradoxically, PROM1 expression correlates with poor prognosis in brain/skin cancers but improved survival in prostate/lung cancers .
In hepatocytes, Prom1 regulates gluconeogenesis via STAT3 signaling, validated using mAB 13A4 in mouse models .
Intestinal Prom1 knockout mice exhibit exacerbated inflammation and dysplasia under AOM/DSS treatment, highlighting its role in mucosal repair .
Melanoma Vaccines: CD133+ melanoma cells elicit anti-tumor immunity, with DDX3X helicase as a co-target .
CRISPR/Cas9 Models: Prom1 knockout in retinal pigment epithelium (RPE) disrupts autophagy, linking it to age-related macular degeneration .
Diagnostic Challenges: Antibodies like CPTC-PROM1-2 show variable specificity across cell lines (e.g., negative in A549, H226) , emphasizing rigorous validation.
Epitope Stability: mAB 13A4’s affinity is disrupted by photoreceptor-specific exon inclusion, affecting retinal studies .
Validation Standards:
Isoform-Specific Antibodies: Develop tools distinguishing PROM1 splice variants to resolve conflicting roles in cancer .
Structural Studies: Resolve PROM1-antibody complexes to refine epitope mapping .
Therapeutic Targeting: Explore PROM1’s role in chemoresistance and immunogenicity across solid tumors .